期刊文献+

局限期小细胞肺癌诱导化疗疗效与放疗时机对中位生存期与中位无进展生存期的影响 被引量:4

下载PDF
导出
摘要 目的观察局限期小细胞肺癌(LSCLC)诱导化疗疗效与放疗时机对患者中位生存期(OS)与中位无进展生存期(PFS)的影响。方法 74例诱导化疗后进行放疗的LSCLC患者作为研究对象,其中早放疗组44例,晚放疗组30例,观察对比两组中位OS和PFS。结果诱导化疗有效后早放疗组中位OS为(36.5±0.4)个月,晚放疗组为(22.4±0.3)个月,两组中位OS对比早放疗组明显更长,差异具有统计学意义(P<0.05)。且两组化疗有效后PFS和无效后中位OS差异均具有统计学意义(P<0.05),但化疗无效后PFS两组差异无统计学意义(P>0.05)。结论局限期小细胞肺癌诱导化疗后无论是否有效均应及早进行放疗。
出处 《中国实用医药》 2015年第4期148-149,共2页 China Practical Medicine
  • 相关文献

参考文献6

二级参考文献23

  • 1杨玲,李连弟,陈育德,Donald Maxwell Parkin.中国肺癌死亡趋势分析及发病、死亡的估计与预测[J].中国肺癌杂志,2005,8(4):274-278. 被引量:168
  • 2张毅,支修益,许庆生,刘宝东,苏雷,王若天,胡牧.新辅助化疗对术中和围术期肺癌患者的影响[J].中华医学杂志,2006,86(23):1647-1648. 被引量:8
  • 3RTOG meta-analysis trialists group: postoperative radiotherapy for non- small celllung cancer. Cochrane Database Sys Rev, 2005, 18(2): CD002142.
  • 4Van MeerbeeckJP, Schil PV, Kramer G, et al. A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage ⅢA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941). Lung Cancer, 2005, 23: 61s (Suppl, abstr7015).
  • 5Sause W, Kolesar P, Taylor S IV, et al. Final results of phase Ⅲ trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group, and Southwest Oncology Group Chest, 2000, 117(2): 358-364.
  • 6Curran W, Scott C, Langer C, et al. Phase Ⅲ comparison of sequential vs.concurrent chemoradiation ofpts with unresected stage Ⅲ non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol, 2000, Abstract 1891.
  • 7Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens ofpaclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase Ⅱ locally advanced multi-modality protocol.J Clin Oncol, 2005, 23(25): 5883-5891.
  • 8Albain KS, Crowley JJ, Turrisi AT, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage ⅢB non-small-cell lung cancer:a Southwest Oncology Group phase Ⅱ study, SWOG9019. J Clin Oncol, 2002, 20(16): 3454-3460.
  • 9Komaki R, Lee JS, Kaplan B, et al. Randomized phase Ⅲ study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage Ⅱ - Ⅲ non-small cell lung cancer: preliminary results. Semin Radiat Oncol, 2002, 12(1 Suppl1): 46-49.
  • 10Doddoli C, Thomas P, Thirion X, et al. Postoperative complications in relation with induction therapy for lung cance. EurJ Cardiothorac Surg, 2001, 20(2): 385-390.

共引文献54

同被引文献25

引证文献4

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部